IABP for Cardiogenic Shock – Cardiology MCQ – Answer

Routine placement of Intra Aortic Balloon Pump (IABP) for cardiogenic shock is a Class —  recommendation as per the 2017 European Society of Cardiology Guidelines for ST-segment elevation myocardial infarction [1,2] – Correct answer: 4. Class III

IABP-SHOCK II trial and its 6 year follow up data [3] did not show any mortality benefit for those who were randomly assigned to receive IABP support. There were no differences in the frequency of recurrent myocardial infarction, repeat revascularization, stroke or rehospitalization for a cardiovascular cause.

References

1. Katz SD, Smilowitz NR, Hochman JS. Another Nail in the Coffin for Intra-Aortic Balloon Counterpulsion in Acute Myocardial Infarction With Cardiogenic Shock. Circulation. 2019 Jan 15;139(3):404-406.
2. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).Eur Heart J. 2018;39:119–177.
3. Thiele H, Zeymer U, Thelemann N, Neuman F, Hausleiter J, Abdel-Wahab M, Meyer-Saraei R, Fuernau G, Eitel C, Hambrecht R, Bohm M, Werdan K, Felix SB, Hennersdorf M, Schneider S, Ouarrak T, Desch S, de Waha-Thiele S. Intra-aortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) Trial.Circulation. 2018;138:395–403.

Back to question